Anti-neoplastoni del dott. Burzynski: le vitamine sintetiche da endovena - Trattamenti  di Burzynski

Il dott. Burzynski, in oltre 20 anni di lavoro, ha curato oltre 3.000 pazienti, iniettando in vena vitamine sintetiche prodotte in laboratorio, chiamate “Neoplastoni”, e capaci di indurre l’apoptosi nelle cellule malate.
Nel 1991, un team della NCI confermò l’attività anticancro degli Antineoplastoni e verificò 5 casi clinici su 7 totali di remissione completa (cioè di scomparsa del cancro).
La FDA richiese allora una documentazione esaustiva dei dati dei pazienti e una stretta aderenza ai regolamenti della FDA per i trias clinici
Nel 2004 il Burzynski Research Institute (BRI) accettò la collaborazione con la Food and Drug Administration (FDA) per gli antineoplastoni A10 e AS2-1 nel trattamento del glioma.
Attualmente il BRI sta conducendo altri 72 trials clinici in molti tipi diversi di cancri.
Le percentuali di successo sono molto alte, vedi: http://www.burzynskiclinic.com/ph/clinical-trials.html

Nel caso dei tumori maligni al cervello, sono stati aperti 4 trials
CAN-1 : (Glioblastoma multiforme e astrocitoma anaplastico)
35 pazienti valutati su un totale di 43.
Risposta completa (Complete Response, CR): 25,7%
Progressione di malattia (Progressive Disease, PD) : 20%
Risposta parziale (Partial Disease, PR) : 22,9%
Malattia stabile (Stable Disease), SD) : 31,4%
CR + PR (objective response) : 48,6%
CR + PR + SD : 80%

BT-9 (Astrocitoma)
13 pazienti valutati su 20
Risposta completa (Complete Response, CR): 23,1%
Progressione di malattia (Progressive Disease, PD) : 7,7%
Risposta parziale (Partial Disease, PR) : 30,8%
Malattia stabile (Stable Disease), SD) : 38,5%

CR + PR (objective response) : 53,8%

CR + PR + SD : 92,3%

BT-11 (Glioma)
18 pazienti valutati su 25
Risposta completa (Complete Response, CR): 16,7%
Progressione di malattia (Progressive Disease, PD) : 33,3%
Risposta parziale (Partial Disease, PR) : 22,2%
Malattia stabile (Stable Disease), SD) : 27,8%
CR + PR (objective response) : 38,9%
CR + PR + SD : 66,7%

BT-13 (bambini con Atrocitoma a basso grado)
8 pazienti valutati su 9
Risposta completa (Complete Response, CR): 37,5%
Progressione di malattia (Progressive Disease, PD) : 0%
Risposta parziale (Partial Disease, PR) : 25%
Malattia stabile (Stable Disease), SD) : 37,5%

CR + PR (objective response) : 62,5%

CR + PR + SD : 100%

Recenti pubblicazioni:
Integrative Cancer Therapies, Vol. 3, No. 3, 257-261 (2004)
Long-Term Survival and Complete Response of a Patient with Recurrent Diffuse Intrinsic Brain Stem Glioblastoma Multiforme
Stanislaw R. Burzynski, MD, PhD

Tratto da: http://ict.sagepub.com/cgi/content/abstract/3/3/257

ALTRO ARTICOLO

Integrative Cancer Therapies, Vol. 4, No. 2, 168-177 (2005)
Long-term Survival of High-Risk Pediatric Patients With Primitive Neuroectodermal Tumors Treated With Antineoplastons A10 and AS2-1
Stanislaw R. Burzynski, MD, PhD
Tratto da: http://ict.sagepub.com/cgi/content/abstract/4/2/168

>>>>>>>>>>>>>>>>>>>>>

ALTRO ARTICOLO:

Integrative Cancer Therapies, Vol. 5, No. 1, 40-47 (2006)
Targeted Therapy With Antineoplastons A10 and AS2-1 of High-Grade, Recurrent, and Progressive Brainstem Glioma
Stanislaw R. Burzynski, MD, PhD
Tratto da: http://ict.sagepub.com/cgi/content/abstract/5/1/40

Burzynski Research Institute - Stanislaw R. Burzynski, MD, PhD
www.cancermed.com

Write up at http://63.173.141.67/treatment/clinicburzynski.html
Dr. Burzynski discovered peptides and amino acid derivatives in the human body that control cancer, not by destroying cancer cells but by correcting them. He named these substances antineoplastons. 
Antineoplastons are nontoxic substances that have shown to be a promising therapy for difficult-to-treat brain cancers, low- and intermediate-grade non-Hodgkin's lymphoma, and many common types of solid tumors.

Note: Antineoplastons have not been approved by the Food and Drug Administration as safe and effective for the treatment of any disease or condition. However, clinical trials are under way on this treatment.

Dr. Burzynski has been approved by the Food and Drug Administration as Principal Investigator in over 70 clinical trial studies. These studies encompass a wide range of cancer types in both children and adults. However, he is best known for treating brain cancer.
After 25 years of experimentation, the outlook for antineoplastons in the treatment of cancer has never been brighter. However, Dr. Burzynski advises that the treatment is still considered experimental, and that no promises of effectiveness can be made.
All residents of the United States must participate and be treated under a current FDA-approved clinical trial or Special Exception. Residents of most other countries must receive FDA permission to ship antineoplastons to that country. All patients are treated on an outpatient basis. The treatment is self-administered and normally free of serious side effects.
Currently there is legislation underway to allow for choice of therapy in treating ones cancer that resulted from Thomas Navarro being denied treatment at Burzynski's clinic. Go to our legislation page for more information on the Thomas Navarro FDA Patient Rights Act (H.R. 3677) or go to www.cancerbusters.com.

Vedi anche: Trattamenti  di Burzynski

"Questo sito WEB vi informa" Non siamo responsabili della correttezza e/o della solvibilita' degli inserzionisti del ns. Network Webmaster  - Copyright © 1998,  Publisher Bamico ltd - All rights reserved  Tutti i diritti riservati - Vietata la copia anche parziale dei contenuti, se non viene citata la fonte